B A Muzembo1, N C Mbendi2, S F Nakayama3. 1. Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan. Electronic address: andersonbasilua@yahoo.fr. 2. Gastroenterology Department, Kinshasa University, Kinshasa, DR Congo. 3. Center for Health and Environmental Risk Research, National Institute for Environmental Studies, Tsukuba, Japan.
Abstract
OBJECTIVES: Dried blood spots (DBS) specimens can be used for hepatitis C virus (HCV) infection screening in cases where serum specimens are difficult to obtain. However, uncertainties surround the sensitivity and specificity of DBS for HCV antibodies (anti-HCV) serology testing. We aimed to evaluate the accuracy of DBS use to screen for HCV infection. STUDY DESIGN: We carried out a systematic review and meta-analysis. METHODS: Medline and EMBASE databases were searched for articles published between 1989 and November 2016. We included studies comparing DBS to plasma/serum specimens to detect anti-HCV in adults. Two authors extracted data and assessed the quality of the studies using an adapted standards for reporting diagnostic accuracy studies (STARD) and independently checked the data for accuracy. Meta-analysis was computed with the bivariate and the hierarchical summary receiver-operating characteristic models. RESULTS: Twelve studies (3307 specimens) were analyzed, where 11 of them evaluated the anti-HCV using enzyme immunoassays (EIAs), and the remaining one used rapid diagnostic tests. The studies were mostly case-controls (83.3%) and from developed countries (66.7%). The overall pooled sensitivity (95% confidence interval; CI) and specificity (95% CI) of DBS to detect anti-HCV was 98.1% (96.1-99.1%) and 99.7% (98.9-99.9%), respectively. In studies using EIAs, the pooled sensitivity and specificity were 97.3% (94.3-98.8%) and 99.6% (98.5-99.9%), respectively. Considering only studies using EIAs, sensitivity analysis excluding one study carried out in people who inject drugs showed the pooled sensitivity of 97.8% (96.2-98.8%) and specificity of 99.5% (98.5-99.9%). CONCLUSIONS: In testing for anti-HCV by means of EIAs, the efficacy of DBS is found to be similar or slightly lower than that of serum specimens. However, the risk of finding negative and positive results that are both false when using DBS remains present. Therefore, further work including optimal storage and processing methodologies are recommended. This is to help establish consensus guidelines for use of DBS specimens for anti-HCV screening.
OBJECTIVES: Dried blood spots (DBS) specimens can be used for hepatitis C virus (HCV) infection screening in cases where serum specimens are difficult to obtain. However, uncertainties surround the sensitivity and specificity of DBS for HCV antibodies (anti-HCV) serology testing. We aimed to evaluate the accuracy of DBS use to screen for HCV infection. STUDY DESIGN: We carried out a systematic review and meta-analysis. METHODS: Medline and EMBASE databases were searched for articles published between 1989 and November 2016. We included studies comparing DBS to plasma/serum specimens to detect anti-HCV in adults. Two authors extracted data and assessed the quality of the studies using an adapted standards for reporting diagnostic accuracy studies (STARD) and independently checked the data for accuracy. Meta-analysis was computed with the bivariate and the hierarchical summary receiver-operating characteristic models. RESULTS: Twelve studies (3307 specimens) were analyzed, where 11 of them evaluated the anti-HCV using enzyme immunoassays (EIAs), and the remaining one used rapid diagnostic tests. The studies were mostly case-controls (83.3%) and from developed countries (66.7%). The overall pooled sensitivity (95% confidence interval; CI) and specificity (95% CI) of DBS to detect anti-HCV was 98.1% (96.1-99.1%) and 99.7% (98.9-99.9%), respectively. In studies using EIAs, the pooled sensitivity and specificity were 97.3% (94.3-98.8%) and 99.6% (98.5-99.9%), respectively. Considering only studies using EIAs, sensitivity analysis excluding one study carried out in people who inject drugs showed the pooled sensitivity of 97.8% (96.2-98.8%) and specificity of 99.5% (98.5-99.9%). CONCLUSIONS: In testing for anti-HCV by means of EIAs, the efficacy of DBS is found to be similar or slightly lower than that of serum specimens. However, the risk of finding negative and positive results that are both false when using DBS remains present. Therefore, further work including optimal storage and processing methodologies are recommended. This is to help establish consensus guidelines for use of DBS specimens for anti-HCV screening.
Authors: Paul G Carty; Christopher G Fawsitt; Paddy Gillespie; Patricia Harrington; Michelle O'Neill; Susan M Smith; Conor Teljeur; Mairin Ryan Journal: Appl Health Econ Health Policy Date: 2021-12-06 Impact factor: 3.686
Authors: Sonia Vázquez-Morón; Beatriz Ardizone Jiménez; María A Jiménez-Sousa; José M Bellón; Pablo Ryan; Salvador Resino Journal: Sci Rep Date: 2019-05-13 Impact factor: 4.379
Authors: Vera Holzmayer; Russell Taylor; Mary C Kuhns; Susan H Gawel; Nicaise Ndembi; Dora Mbanya; Lazare Kaptue; Mary A Rodgers; Gavin Cloherty Journal: Sci Rep Date: 2022-03-08 Impact factor: 4.379
Authors: Beth Catlett; Mitchell Starr; Dorothy A Machalek; Thidarat Danwilai; Michael Palmer; Andrew Kelly; John Kaldor; Gregory J Dore; David Darley; Gail Matthews; Philip H Cunningham Journal: J Clin Virol Plus Date: 2022-06-24
Authors: Nishi Prabdial-Sing; Lucinda Gaelejwe; Lillian Makhathini; Jayendrie Thaver; Morubula Jack Manamela; Susan Malfeld; C Wendy Spearman; Mark Sonderup; Andrew Scheibe; Katherine Young; Harry Hausler; Adrian J Puren Journal: Health Sci Rep Date: 2021-02-11
Authors: Paul G Carty; Michael McCarthy; Sinead O'Neill; Patricia Harrington; Michelle O'Neill; Conor Teljeur; Susan M Smith; Máirín Ryan Journal: HRB Open Res Date: 2020-10-27